Video

Video Report: Highlights From the World Conference on Lung Cancer


 

AMSTERDAMDr. Roy S. Herbst cites post hoc analysis of the FLEX trial as a highlight of IASLC's World Conference on Lung Cancer. Investigators quantified EGFR number by an immunohistochemistry stain. Tumors with high EGFR levels had a significantly better response to cetuximab than did tumors with low EGFR levels. His second highlight is a pilot study with five patients that used PET imaging and labeled erlotinib to noninvasively quantify EGFR expression in tumor cells, precluding the need for biopsied tissue.

Recommended Reading

EBUS Equals Mediastinoscopy for NSCLC Staging
MDedge Hematology and Oncology
Accurate Biomarker Testing Key to Experimental MetMAb in Lung Cancer
MDedge Hematology and Oncology
European Trial Upholds Use of Erlotinib in EGFR-Mutant Lung Cancer
MDedge Hematology and Oncology
European Trial Upholds Use of Erlotinib in EGFR-Mutant Lung Cancer
MDedge Hematology and Oncology
Smoking Bans, Taxes Could Save Nearly $2 Billion in Health Costs
MDedge Hematology and Oncology
FDA Unveils Graphic Cigarette Packaging Intended to Deter Smoking
MDedge Hematology and Oncology
CT Screening Cuts Lung Cancer Mortality; Raises Policy Questions
MDedge Hematology and Oncology
Gene Test Refines Prognosis For Lung Cancer
MDedge Hematology and Oncology
International Association Favors CT Screening of Heavy Smokers
MDedge Hematology and Oncology
International Association Favors CT Screening of Heavy Smokers
MDedge Hematology and Oncology